# Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis

> **NCT02144272** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 41 (actual)

## Conditions studied

- Inflammatory Arthritis

## Interventions

- **DRUG:** LY3114062 SC
- **DRUG:** Placebo
- **DRUG:** LY3114062 IV

## Key facts

- **NCT ID:** NCT02144272
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-05
- **Final completion:** 2015-06
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02144272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02144272, "Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02144272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*